Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed.
Show original
This critical step marks the official completion of the clinical trial data collection phase, laying a solid foundation for subsequent data analysis and results evaluation. The company stated that the advancement of this study will further enrich the clinical application data of Ameluz® in the field of dermatological disease treatment.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
The three major U.S. stock indexes closed lower collectively
金色财经•2026/02/27 21:08
The three major U.S. stock indexes closed lower collectively.
金色财经•2026/02/27 21:08
This week, CME open interest dropped by 1.78%.
AIcoin•2026/02/27 21:02
SpaceX reportedly considering filing for a secret U.S. IPO as early as March
金色财经•2026/02/27 20:39
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$65,567.98
-2.56%
Ethereum
ETH
$1,927.47
-4.79%
Tether USDt
USDT
$0.9999
-0.02%
BNB
BNB
$611.76
-1.61%
XRP
XRP
$1.35
-2.68%
USDC
USDC
$1.0000
+0.01%
Solana
SOL
$81.66
-5.15%
TRON
TRX
$0.2826
-1.13%
Dogecoin
DOGE
$0.09329
-3.53%
Cardano
ADA
$0.2777
-2.54%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now